Creative Medical Technology Holdings, In - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CELZ Nasdaq 2836 www.creativemedicaltechnology.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Creative Medical Technology Holdings, In

Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells - Jul 17th, 2025 7:15 am
Creative Medical Technology Holdings Receives Notice of Allowance for ImmCelz™ for Treatment of Heart Failure and/or Post Infarct Pathological Remodeling - Jul 11th, 2025 6:01 am
Companies Like Creative Medical Technology Holdings (NASDAQ:CELZ) Are In A Position To Invest In Growth - Apr 27th, 2025 7:41 am
Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain - Mar 20th, 2025 5:50 am
Creative Medical Technology Holdings, Inc.'s (NASDAQ:CELZ) Shift From Loss To Profit - Mar 16th, 2025 8:14 am
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds - Mar 6th, 2025 6:10 am
Creative Medical Technology Holdings Applauds Presidential Initiative to Expand IVF Access, Showcasing OvaStem® Program's Success and Growth Potential - Feb 20th, 2025 6:00 am
Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™ - Feb 14th, 2025 5:00 am
Creative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program - Feb 11th, 2025 7:25 am
Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development - Feb 5th, 2025 6:25 am
Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain - Jan 30th, 2025 7:25 am
Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment - Nov 13th, 2024 7:00 am
Creative Medical Technology Holdings Third Quarter 2024 Earnings: US$0.75 loss per share (vs US$1.02 loss in 3Q 2023) - Nov 10th, 2024 7:19 am
Creative Medical to sell 418,552 shares at $4.42 in registered direct offering - Oct 24th, 2024 6:21 am
Creative Medical Technology Holdings Announces $1.85 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Oct 23rd, 2024 6:00 am
Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program - Jul 24th, 2024 7:00 am